FY2025 · ended Dec 31, 2025 · Revenue $283.06M, +20.4% YoY · Filed Feb 26, 2026
Aurinia Pharmaceuticals Inc. (AUPH) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $283.1 million and net income of $287.2 million. As of Sep 30, 2026 it held $45.8 million in cash and investments and $58.7 million in total debt.
Revenue (TTM)
$321.74M
+21.0% vs year-ago TTM
Net income (TTM)
$314.27M
+303.7% vs year-ago TTM
Operating cash flow (TTM)
$177.16M
+47.5% vs year-ago TTM
Free cash flow
$-63.54M
-23.0% vs prior year
EPS (TTM)
$2.31
+320.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
132.97M
-3.2% vs prior year
Net cash
$-12.87M
as of Sep 30, 2026
Operating margin
48.6%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AUPH (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Edmonton, Alberta, Canada
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1600620
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $283.1M | $235.1M | $175.5M | $134.0M | $45.6M |
| Operating income | $104.9M | -$4.7M | -$91.7M | -$111.5M | -$180.7M |
| Net income | $287.2M | $5.8M | -$78.0M | -$108.2M | -$181.0M |
| Diluted EPS | $2.07 | $0.04 | -$0.54 | -$0.76 | -$1.40 |
| Operating cash flow | $135.7M | $44.4M | -$33.5M | -$79.5M | -$157.7M |
| Total assets | $751.6M | $550.6M | $548.1M | $470.9M | $543.4M |
| Total liabilities | $170.3M | $173.2M | $170.1M | $65.4M | $64.3M |
| Stockholders' equity | $581.3M | $377.5M | $378.0M | $405.4M | $479.1M |
| Cash and investments | $80.2M | $83.4M | $350.6M | $389.3M | $446.6M |
| Total debt | $74.8M | $79.4M | $97.6M | $8.1M | $8.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 30, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 30, 2026 | Oct 30, 2026 |
| 8-K |
Current report
Other events
|
Aug 19, 2026 | Aug 19, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 4, 2026 | Jun 3, 2026 |
All 615 Aurinia Pharmaceuticals Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.